Abstract
Several lines of evidence have extensively demonstrated that peroxynitrite plays a pivotal role in Central Nervous System (CNS) injuries. The present study was aimed at elucidating the molecular mechanism by which propofol attenuates peroxynitrite-mediated injury in the brain. Primary cultured astroglial cells were incubated for 18 h with a known peroxynitrite donor (SIN-1,3 μM) in the presence or absence of propofol (40 μM, 80 mM and 160 μM). The protective effects of propofol were evaluated by MTT cytotoxicity assay, LDH release, and caspase-3 activation by Western blot analysis. Appropriate propofol concentrations (ranging from 40 μM to 160 μM) significantly increased HO- 1 expression and attenuated SIN-1-mediated cytotoxicity and caspase-3 activation. The protective effects of propofol were mitigated by the addition of tin-mesoporphirin (SnMP), a potent inhibitor of HO activity. The addition of a specific synthetic inhibitor of NF-κB abolished propofol-mediated HO-1 induction, suggesting a possible role for this nuclear transcriptional factor in our experimental conditions. These findings indicate that propofol attenuates peroxynitritemediated apoptosis in astroglial cells, a property that may be relevant in both physiological and pathological processes in the CNS.
Keywords: heme oxygenase, peroxynitrite, astrocytes, apoptosis, propofol, caspase-3
Current Neurovascular Research
Title: Propofol Inhibits Caspase-3 in Astroglial Cells: Role of Heme Oxygenase-1
Volume: 2 Issue: 2
Author(s): Rosaria Acquaviva, Agata Campisi, Giuseppina Raciti, Roberto Avola, Maria Luisa Barcellona, Luca Vanella and Giovanni Li Volti
Affiliation:
Keywords: heme oxygenase, peroxynitrite, astrocytes, apoptosis, propofol, caspase-3
Abstract: Several lines of evidence have extensively demonstrated that peroxynitrite plays a pivotal role in Central Nervous System (CNS) injuries. The present study was aimed at elucidating the molecular mechanism by which propofol attenuates peroxynitrite-mediated injury in the brain. Primary cultured astroglial cells were incubated for 18 h with a known peroxynitrite donor (SIN-1,3 μM) in the presence or absence of propofol (40 μM, 80 mM and 160 μM). The protective effects of propofol were evaluated by MTT cytotoxicity assay, LDH release, and caspase-3 activation by Western blot analysis. Appropriate propofol concentrations (ranging from 40 μM to 160 μM) significantly increased HO- 1 expression and attenuated SIN-1-mediated cytotoxicity and caspase-3 activation. The protective effects of propofol were mitigated by the addition of tin-mesoporphirin (SnMP), a potent inhibitor of HO activity. The addition of a specific synthetic inhibitor of NF-κB abolished propofol-mediated HO-1 induction, suggesting a possible role for this nuclear transcriptional factor in our experimental conditions. These findings indicate that propofol attenuates peroxynitritemediated apoptosis in astroglial cells, a property that may be relevant in both physiological and pathological processes in the CNS.
Export Options
About this article
Cite this article as:
Acquaviva Rosaria, Campisi Agata, Raciti Giuseppina, Avola Roberto, Barcellona Luisa Maria, Vanella Luca and Volti Li Giovanni, Propofol Inhibits Caspase-3 in Astroglial Cells: Role of Heme Oxygenase-1, Current Neurovascular Research 2005; 2 (2) . https://dx.doi.org/10.2174/1567202053586820
DOI https://dx.doi.org/10.2174/1567202053586820 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Optical Coherence Tomography for Complete Management of Patients with Diabetic Retinopathy
Current Diabetes Reviews Medical Management of the Diabetic Patient with Coronary Artery Disease
Current Pharmaceutical Design Lipid Based Nanosystems for Curcumin: Past, Present and Future
Current Pharmaceutical Design Vasorelaxation Caused by Cannabinoids: Mechanisms in Different Vascular Beds
Current Vascular Pharmacology Erratum
Current Medicinal Chemistry Directing Cardiomyogenic Differentiation and Transdifferentiation By Ectopic Gene Expression – Direct Transition Or Reprogramming Detour?
Current Gene Therapy How Recent Patents Have Changed our Clinical Approach in Cardio-Thoracic Surgery
Recent Patents on Regenerative Medicine MicroRNAs in Organogenesis and Disease
Current Molecular Medicine The Nrf2-ARE Pathway: A Valuable Therapeutic Target for the Treatment of Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Systems Biology Approaches and Metabolomics for Understanding Japanese Traditional Kampo Medicine
Current Pharmacogenomics and Personalized Medicine Lymphatic Endothelial Cells, Inflammatory Lymphangiogenesis, and Prospective Players
Current Medicinal Chemistry A Short Review of Diffusion Models and their Possibilities to Enhance Imaging Biomarkers for Neurodegenerative Diseases
Current Medical Imaging Pancreatic Islet Transplantation in Type 1 Diabetes Mellitus: An Update on Recent Developments
Current Diabetes Reviews Do RAS Inhibitors Protect the Brain from Cerebral Ischemic Injury?
Current Hypertension Reviews Platelets in Atherothrombosis: New and Evolving Roles
Current Pharmaceutical Design Development of New Fibrinolytic Agents
Current Pharmaceutical Design Human Mesenchymal Stem Cells Increases Expression of α-Tubulin and Angiopoietin 1 and 2 in Focal Cerebral Ischemia and Reperfusion
Current Neurovascular Research Remote Ischemic Conditioning Improves Cognitive Function During Cerebral Vascular Injury Through the Induction of Autophagy
Current Neurovascular Research The Etiology of Hypertension in the Metabolic Syndrome Part Three: The Regulation and Dysregulation of Blood Pressure
Current Vascular Pharmacology Metalloproteinases and Metalloproteinase Inhibitors in Age-Related Diseases
Current Pharmaceutical Design